News

Vernalis receives $1.5 million milestone payment from Novartis

Vernalis Plc has received a milestone payment of $1.5 million from Novartis in connection with the start of a Phase 1 clinical trial of a compound to treat cancer. The payment stems from a 2004 research collaboration between Vernalis and the Novartis Institutes for BioMedical Research under which Novartis agreed to fund research into a number of candidate inhibitors of a protein that plays an important role in the proliferation of cancer cells.

UK regulator backs use of animal-human embryos for research

Scientists should be allowed to create hybrid embryos, combining some human and some animal material, in order to try and derive a new source of embryonic stem cells for research, according to the UK Human Fertilisation and Embryology Authority (HFEA).

DSM Venturing invests €2 million in Jurilab

DSM Venturing BV, the venture capital arm of Royal DSM NV of the Netherlands, has made a €2 million equity investment in Jurilab Oy, in what Jurilab’s chief executive, Kari Paukkeri, describes as a “strategic alignment.”

Antisoma reports positive Phase 2 result for cancer drug

Antisoma Plc has reported positive results from a Phase 2 trial of its cancer drug, ASA404, which is intended to treat non-small-cell lung cancer. Data from the trial will be disclosed at the World Lung Cancer Conference in Soeul, Korea on 5 September 2007.

US patent reform would have worldwide impact

A proposed reform of US patent law, which is now before the US Congress, could have a significant impact on European life science companies doing business in the US as well as on efforts towards international patent harmonisation.